ACLX-10.06%8.3%
AVBP+44.80%8.3%
CGEM+164.71%8.3%
CRSP+9.54%8.3%
JANX-28.44%8.3%
NRIX+163.51%8.3%
NUVB+138.97%8.3%
NUVL0.00%8.3%
PTGX+168.48%8.3%
RIGL+10.58%8.3%
RVMD+465.96%8.3%
ZYME+89.87%8.3%
As of Aug 24, 2026, 4:53 AM ET
Biotech '25: Oncology & Immunotherapy Constituents
Arcellx, Inc.ACLX | 8.3% | 0.00% | 0.00% | 0.00% | 0.00% | -1.67% | 0.00% | -4.64% | -7.60% | 281.61% | -10.06% | $3.75B |
ArriVent BioPharma, Inc.AVBP | 8.3% | -0.21% | -7.23% | -8.23% | -2.35% | 44.73% | 26.77% | 61.78% | 19.98% | 61.78% | 44.80% | $1.36B |
CRISPR Therapeutics AGCRSP | 8.3% | 2.37% | 10.04% | 27.85% | 23.98% | 13.46% | -1.06% | 74.03% | 22.20% | -52.41% | 9.54% | $5.74B |
Cullinan Therapeutics, Inc.CGEM | 8.3% | 1.40% | 10.44% | 26.78% | 31.39% | 109.47% | 39.87% | 177.24% | 20.24% | -25.75% | 164.71% | $1.33B |
Janux Therapeutics, Inc.JANX | 8.3% | 0.64% | 5.27% | 13.44% | 14.63% | 26.01% | 27.77% | -38.44% | -62.13% | -39.26% | -28.44% | $1.06B |
Nurix Therapeutics, Inc.NRIX | 8.3% | -1.22% | 2.93% | 14.29% | 15.12% | 40.85% | 67.31% | 134.80% | 11.24% | -18.04% | 163.51% | $2.77B |
Nuvalent, Inc.NUVL | 8.3% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -24.14% | 0.00% | $1.62B |
Nuvation Bio Inc.NUVB | 8.3% | 1.46% | 8.79% | 7.94% | 9.48% | -22.66% | 17.26% | 287.15% | 140.63% | -25.64% | 138.97% | $2.41B |
Protagonist Therapeutics, Inc.PTGX | 8.3% | 2.41% | 4.07% | 13.38% | 12.94% | 76.69% | 67.59% | 220.17% | 270.25% | 211.19% | 168.48% | $9.92B |
Revolution Medicines, Inc.RVMD | 8.3% | -1.07% | 1.90% | 10.69% | 11.69% | 162.98% | 105.31% | 505.38% | 379.97% | 705.93% | 465.96% | $44.53B |
Rigel Pharmaceuticals, Inc.RIGL | 8.3% | 1.41% | 9.21% | 24.90% | 24.67% | 7.14% | 32.10% | 152.00% | 267.71% | 21.40% | 10.58% | $849.1M |
Zymeworks Inc.ZYME | 8.3% | 7.90% | 17.89% | 25.42% | 30.67% | 8.89% | 23.10% | 140.52% | 151.71% | -12.83% | 89.87% | $2.11B |
| Theme return | — | 1.26% | 5.28% | 11.30% | 13.79% | 38.47% | 35.92% | 141.00% | 105.86% | 172.41% | 98.43% | — |
| Average | 8.3% | 1.26% | 5.28% | 13.04% | 14.35% | 38.82% | 33.84% | 142.50% | 101.18% | 90.32% | 101.49% | $6.45B |
| Median | 8.3% | 1.02% | 4.67% | 13.41% | 13.79% | 19.74% | 27.27% | 137.66% | 21.22% | -15.43% | 67.34% | $2.26B |
| Std Dev | 0.0% | 2.31% | 6.24% | 11.28% | 11.11% | 51.25% | 30.81% | 143.15% | 133.65% | 211.21% | 131.11% | $11.74B |
| Min | 8.3% | -1.22% | -7.23% | -8.23% | -2.35% | -22.66% | -1.06% | -38.44% | -62.13% | -52.41% | -28.44% | $849.1M |
| Max | 8.3% | 7.90% | 17.89% | 27.85% | 31.39% | 162.98% | 105.31% | 505.38% | 379.97% | 705.93% | 465.96% | $44.53B |
| % Positive Tickers | 58.33% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 41.67% | 75.00% |
Default: Wgt ↓ · Click headers to sort · Shift+click secondary
About this theme
Biotech '25: Oncology & Immunotherapy tracks 12 publicly listed stocks in this theme: ACLX, AVBP, CGEM, CRSP, JANX, NRIX, NUVB, NUVL, PTGX, RIGL, RVMD, ZYME. See the constituent table for details.